Occlutech
Occlutech is a medical device company that develops and commercializes minimally invasive Nitinol-based cardiac implants, including occluders for congenital heart defects and the Atrial Flow Regulator for heart failure, serving interventional cardiologists across approximately 85 countries.
- Company typePrivate
- Founded2003
- HeadquartersHelsingborg, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Occlutech does
Occlutech is a medical device company founded in 2003 that develops, manufactures, and commercializes minimally invasive cardiac implants based on proprietary Nitinol braiding technology. The company is legally domiciled in Switzerland as Occlutech Holding AG, with finance and distribution operations in Helsingborg, Sweden, and manufacturing and R&D facilities in Jena, Germany, and Istanbul, Turkey. Its product portfolio spans three therapeutic areas: Congenital Heart Disease (ASD, PDA, mVSD occluders), Adult Intervention and Stroke Prevention (PFO, UNI, PLD occluders), and Heart Failure (the Atrial Flow Regulator, an interatrial shunting device). Differentiated design features include a left-atrial hubless ASD Occluder and conformable braided wire architecture protected by over 200 patents.
The company sells directly in France, Germany, Italy, the Nordics, and the United Kingdom, and through a distribution partner network spanning approximately 85 countries, with over 220,000 occluders implanted across more than 70 countries. In the United States, Occlutech commercializes the ASD Occluder exclusively through B. Braun Interventional Systems Inc. following FDA approval in December 2023. Revenue is generated through per-unit hardware sales of implants and delivery accessories, supported by clinical evidence dissemination, medical congress presence, and physician education. 2025 unaudited revenue was EUR 49.4 million with approximately 85% derived from Europe and the US, representing a 15.7% CAGR over three years.
Customer segments include pediatric and adult patients with congenital heart defects, adult patients at risk of cryptogenic stroke, and heart failure patients with preserved or reduced ejection fraction who remain symptomatic despite optimal medical therapy. The company is positioning for accelerated US expansion and a potential heart failure indication for the AFR, supported by the FROST-HF pivotal study and FDA Breakthrough Device designation. A binding agreement announced in February 2026 for Alkem MedTech to acquire up to 55% of Occlutech Holding AG for EUR 99.4 million, at a total equity value of EUR 180.7 million, represents a major ownership transition expected to close by June 2026 and provide additional capital and strategic backing from Alkem Laboratories.
Occlutech firmographics
Firmographics- Name
- Occlutech
- Legal name
- Occlutech Holding AG
- Website
- https://occlutech.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Occlutech is a medical device company that develops and commercializes minimally invasive Nitinol-based cardiac implants, including occluders for congenital heart defects and the Atrial Flow Regulator for heart failure, serving interventional cardiologists across approximately 85 countries.
- Ownership category
- akta.pro rank
Occlutech industry classification
Industry- Product category
- Cardiac Implants
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where Occlutech is headquartered
LocationHeadquarters
- HQ city
- Helsingborg
- HQ country
- Sweden
- HQ region
- Europe
Offices5 records
Markets served
Occlutech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales: Occlutech generates revenue through the sale of its proprietary cardiac implants and delivery accessories. Products include occluders (ASD, PFO, PDA, mVSD, UNI, PLD) and the Atrial Flow Regulator (AFR). Revenue is derived from direct sales in key European markets and through distribution partners globally, with a growing US market following FDA approval of the ASD Occluder in 2023.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Occlutech product offering
Product offeringCore offering
Occlutech designs, manufactures, and commercializes minimally invasive cardiac implants built on proprietary Nitinol braiding technology. Its portfolio includes occluders for congenital heart defects (ASD, PDA, mVSD), adult intervention occluders (PFO, UNI, PLD), and the Atrial Flow Regulator (AFR) for heart failure treatment, supported by delivery system accessories. Products are sold directly to hospitals and interventional cardiologists in key European markets and through distributor networks covering approximately 85 countries.
Product overview
Occlutech offers a broad portfolio of minimally invasive cardiac implants designed to address three main therapeutic areas: Congenital Heart Disease, Stroke Prevention & Adult Intervention, and Heart Failure. The product portfolio centers on occluder devices (ASD, PFO, PDA, mVSD, UNI, PLD) for closing various cardiac defects, and the Atrial Flow Regulator (AFR) for heart failure treatment. Supporting accessories include delivery systems (Pistol Pusher, Delivery Set III), sizing balloons, and guide wires. The company operates with a proprietary Nitinol-based braided wire technology and self-centering design across its device range. Products are sold in approximately 85 countries with manufacturing and R&D facilities in Germany and Turkey.
Differentiator
Problem solved
Functional benefit
Brands
- Atrial Flow Regulator (AFR): Cardiac implant designed to address unmet needs of heart failure patients through interatrial shunting
- ASD Occluder
- PFO Occluder
- PDA Occluder
- mVSD Occluder
- UNI Occluder
- PLD Occluder
Products and services
- ASD Occluder Self-centering occluder for percutaneous transcatheter closure of ostium secundum-type atrial septal defects, featuring double discs with waist and flexible wire design for conformable deployment. Sold in over 70 countries with 220,000+ occluders implanted globally.
- PFO Occluder Occluder device for closure of Patent Foramen Ovale (PFO) to prevent cryptogenic stroke by closing the flap-like opening between the atria in adult patients.
- PDA Occluder Minimally invasive transcatheter closure device for Patent Ductus Arteriosus (PDA), featuring an aortic disc connected to a conical-shaped shank made of braided Nitinol.
- mVSD Occluder Occluder device designed for transcatheter closure of muscular ventricular septal defects (mVSD), a type of congenital heart defect.
- UNI Occluder Universal occluder device for various cardiac defect closures, part of Occlutech's adult intervention portfolio.
- PLD Occluder Occluder device for patent ductus ligation (PLD) procedures, part of Occlutech's adult intervention product portfolio.
- Atrial Flow Regulator (AFR) CE-marked cardiac implant for interatrial shunting in heart failure patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction who remain symptomatic despite optimal medical therapy. Two-disc configuration with central fenestration for controlled left-to-right atrial shunt. Available in two waist-heights, disc sizes, and fenestration diameters.
- Occlutech Pistol Pusher Delivery system accessory for precise placement and deployment of the ASD Occluder device during transcatheter procedures.
- Occlutech Delivery Set III Delivery catheter system for implanting Occlutech occluder devices through peripheral blood vessels to the heart.
- Occlutech Sizing Balloon Balloon catheter used to measure the size of cardiac defects such as ASD and PFO prior to device selection and implantation.
- Occlutech Stiff Guide Wire Guide wire providing stiffness and support for catheter navigation during Occlutech device implantation procedures.
Quantifiable outcome
- Higher rate of successful defect closure with less major complications vs. comparator device in randomized trial (Kenny et al., Catheter Cardiovasc Interv 2019)
- +4 more outcomes
Companies that use Occlutech
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles1 record
Occlutech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Occlutech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- B. Braun Interventional Systems Inc.coreExclusive distribution partnership for the US market. B. Braun Interventional Systems assumes commercialization activities for the Occlutech ASD Occluder and Occlutech Pistol Pusher, with support from the Occlutech global team. The partnership leverages B. Braun's established interventional cardiology and congenital heart disease channel presence. Signed in May 2022, with B. Braun initiating commercialization following FDA approval in December 2023.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
Occlutech competitors and assessment
Company assessmentDirect peers
- V-Wave: V-Wave is developing interatrial shunt devices (Ventura Shunt) for heart failure patients, directly competing with Occlutech's AFR in the same novel therapeutic category targeting HFpEF and HFrEF populations.
- Corvia Medical: Corvia Medical is developing the InterAtrial Shunt Device (IASD) for heart failure with preserved ejection fraction (HFpEF), directly competing with Occlutech's Atrial Flow Regulator (AFR) in the same interatrial shunting therapeutic category.
- pfm medical: pfm medical produces Nitinol-based cardiac occluders (e.g., Nit-Occlud, CERA) for ASD and PFO closure in European and emerging markets, directly competing with Occlutech's Nitinol occluder portfolio using similar material science.
- Lifetech Scientific: Lifetech Scientific manufactures and markets a range of cardiac occluders (Cera, HeartR, etc.) for ASD, PFO, PDA, and VSD closure, directly competing with Occlutech's occluder portfolio particularly in Asia-Pacific and emerging markets.
- W. L. Gore & Associates (Gore Medical): Gore Medical produces the GORE CARDIOFORM Septal Occluder for ASD closure and the GORE CARDIOFORM PFO Occluder, directly competing with Occlutech's PFO and ASD occluders in the US and European markets with comparable transcatheter delivery systems.
Emerging players
- SentreHEART: SentreHEART developed LARIAT and related left atrial appendage closure technologies serving structural heart patients, an adjacent peer with overlapping interventional cardiology customer relationships and physician call points.
- Alleviant Medical: Alleviant Medical is developing a transcatheter interatrial shunt device for heart failure (No-Implant Approach), competing with Occlutech's AFR with a differentiated technology that creates an alternative path in the same therapeutic market.
- Cardia (Cardia Innovation): Cardia Innovation develops PFO and ASD occluder devices using Nitinol technology, an emerging competitor in the structural heart closure space targeting similar interventional cardiology customers.
Broad incumbents
- Abbott: Abbott owns the Amplatzer portfolio (Amplatzer Septal Occluder, PFO Occluder, etc.), the dominant global franchise in transcatheter cardiac defect closure that directly competes with Occlutech's occluder devices across all major markets and serves as the benchmark for physician adoption.
- Boston Scientific: Boston Scientific is a major cardiovascular device company with structural heart and interventional cardiology offerings, including competitive occluder technologies and a broad sales channel that overlaps with Occlutech's target hospital accounts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Occlutech social profiles
Digital presenceOcclutech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Occlutech leadership team
Management profileNumber of profiles
Profiles10 records
Occlutech subsidiaries and ownership
Company hierarchySubsidiaries4 records
Occlutech funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Occlutech M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Occlutech
What does Occlutech do?
Occlutech designs, manufactures, and commercializes minimally invasive cardiac implants built on proprietary Nitinol braiding technology. Its portfolio includes occluders for congenital heart defects (ASD, PDA, mVSD), adult intervention occluders (PFO, UNI, PLD), and the Atrial Flow Regulator (AFR) for heart failure treatment, supported by delivery system accessories. Products are sold directly to hospitals and interventional cardiologists in key European markets and through distributor networks covering approximately 85 countries.
Is Occlutech a public or private company?
Occlutech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Occlutech founded?
Occlutech was founded in 2003. It employs 51 to 100 people.
Where is Occlutech based?
Occlutech is headquartered in Helsingborg, Sweden, in the Europe region.
How does Occlutech make money?
One revenue line is on record: medical Device Sales.
Who are Occlutech's main competitors?
Direct peers on record are V-Wave, Corvia Medical, pfm medical, Lifetech Scientific and W. L. Gore & Associates (Gore Medical). Emerging players are SentreHEART, Alleviant Medical and Cardia (Cardia Innovation). Broad incumbents are Abbott and Boston Scientific.
Does Occlutech have an API?
No public API is recorded for Occlutech.
What industry is Occlutech in?
Occlutech's product category is Cardiac Implants. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339113 and its SIC code is 3842.